Award
National Cancer Institute 5P50CA265793-03
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy
Recipient
Washington University in Saint Louis
Award Amount
$518,102.00
Ceiling
$518,102.00
Awarded
September 22, 2025
Identifier
5P50CA265793-03
NIH/NCI awarded $518,102 to Washington University in Saint Louis for a project targeting HSPA proteins in advanced and recurrent endometrial cancer therapy, involving clinical trials and biomarker studies.
Description
The project involves studying a drug called SHetA2 for endometrial cancer treatment, including clinical trials, mechanism studies, and biomarker identification. It is part of a Phase 1 clinical trial with a subsequent Phase 2 expansion. The project is funded by the NIH/NCI with a total budget of $518,102 for FY 2025 and duration from August 23, 2023, to July 31, 2028. The organization involved is Washington University in Saint Louis.